This is a working overview of CJC-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-02. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
=== As an allergen === Whether hydrolyzed vegetable protein is an allergen or not is contentious. According to European law, wheat and soy are subject to allergen labelling in terms of Regulation (EU) 1169/2011 on food information to consumers. Since wheat and soy used for the production of HVP are not exempted from allergen labelling for formal reasons, HVP produced by using those raw materials has to be labelled with a reference to wheat or soy in the list of ingredients. Nevertheless, strong evidence indicates at least aHVP is not allergenic, since proteins are degraded to single amino acids which are not likely to trigger an allergic reaction. A 2010 study has shown that aHVP does not contain detectable traces of proteins or IgE-reactive peptides. This provides strong evidence that aHVP is very unlikely to trigger an allergic reaction to people who are intolerant or allergic to soy or wheat. Earlier peer-reviewed animal studies done in 2006 also indicate that soy-hypersensitive dogs do not react to soy hydrolysate, a proposed protein source for soy-sensitive dogs. There are reports of a cosmetic-grade aHVP, Glupearl 19S (GP19S), inducing anaphylaxis when present in soap. Unlike food aHVP, this Japanese wheat aHVP is only very mildly hydrolyzed. The unusual chemical condition makes GP19S more allergenic than pure gluten. Newer regulations for cosmetic hydrolyzed wheat protein have been developed in response, requiring an average molecular mass of less than 3500 Da – about 35 residues long.
== Structure == The fundamental structure of a cerebroside is ceramide. Monoglycosyl and oligoglycosylceramides having a mono or polysaccharide bonded glycosidically to the terminal OH group of ceramide are defined as cerebrosides. Sphingosine is the main long-chain base present in ceramide. Galactosylceramide is the principal glycosphingolipid in brain tissue. Galactosylceramides are present in all nervous tissues, and can compose up to 2% dry weight of grey matter and 12% of white matter. They are major constituents of oligodendrocytes. Glucosylceramide is found at low levels in animal cells such as the spleen, erythrocytes, and nervous tissues, especially neurons. Glucosylceramide is a major constituent of skin lipids, where it is essential for lamellar body formation in the stratum corneum and to maintain the water permeability barrier of the skin. Glucosylceramide is the only glycosphingolipid common to plants, fungi and animals. It is usually considered to be the principal glycosphingolipid in plants. It is a major component of the outer layer of the plasma membrane. Galactosylceramides have not been found in plants. Monogalactosylceramide is the largest single component of the myelin sheath of nerves. Cerebroside synthesis can therefore give a measurement of myelin formation or remyelination. The sugar moiety is linked glycosidically to the C-1 hydroxyl group of ceramide, such as in lactosylceramide. Cerebrosides containing a sulfuric ester (sulfate) group, known as sulfatides, also occur in the myelin sheath of nerves.
No more extortions, no more killings of innocent people! Zetas in the state of Veracruz and politicians helping them: This is going to happen to you, or we can shoot you as we did to you guys before too. People of Veracruz, do not allow yourselves to be extorted; do not pay for protection; if you do is because you want to. This is the only thing these people (Los Zetas) can do. This is going to happen to all the Zeta-shits who continue to operate in Veracruz. This territory has a new proprietor. The Blog del Narco reported on 21 September 2011 that the message was supposedly signed by Gente Nueva, an enforcer group that works for Joaquín Guzmán Loera, the top boss of the Sinaloa cartel. Nonetheless, on 27 September 2011, the CJNG released a video claiming they had carried out these attacks. They apologized for the massacres in Veracruz but reiterated their efforts to fight off Los Zetas, who, they claimed, "are not invincible." In the CJNG video, five men wearing balaclavas and completely black clothing are shown sitting behind a table. Then the man with the microphone states that the Matazetas are "warriors without a face, but proudly Mexicans", and that their objective is to eradicate Los Zetas. They claim in the video that they respect the Mexican Armed Forces and understand the government's stance against the drug cartels. The men in the video state that they understand and respect the government's decision of refusing to negotiate with the cartels. They also criticize the politicians who have protected Los Zetas.
Sources: en.wikipedia.org
The D'/D3 domain: Binds to factor VIII, heparin, and P-selectin. The A1 domain: Binds to the platelet GPIb-receptor, collagen types IV and VI, heparin, and osteoprotegerin. The A2 domain: Unfolds to expose the cleavage site for ADAMTS13 protease, which cleaves VWF into smaller multimers. Unfolding is influenced by blood shear flow, calcium binding, and a "vicinal disulfide" at the A2-domain's C-terminus. The A3 domain: Acts as the primary collagen binding site for VWF, binding to collagen types I and III. The C4 domain: Contains an RGD motif that binds to platelet integrin αIIbβ3. The CK (cystine knot) domain at the protein's C-terminal end: Involved in VWF dimerization. VWF is one of the few proteins carrying ABO blood group antigens. After glycosylation in the Golgi apparatus, VWF is packaged into storage granules, Weibel–Palade bodies (WPBs) in endothelial cells, and α-granules in platelets.
=== Vascular endothelium and microangiopathy === An upregulation of vascular cell adhesion molecule-1 is observed in NL tissue, indicating leukocyte aggregation and an inflammatory response. Furthermore, there is a reduced VEGF expression along with AGE-mediated cross-linking, reducing ECM fluidity. Both factors impair new vessel growth, lead to poor oxygenation, and impair tissue healing.
Fibrils (from Latin fibra) are structural biological materials found in nearly all living organisms. Not to be confused with fibers or filaments, fibrils tend to have diameters ranging from 10 to 100 nanometers (whereas fibers are micro to milli-scale structures and filaments have diameters approximately 10–50 nanometers in size). Fibrils are not usually found alone but rather are parts of greater hierarchical structures commonly found in biological systems. Due to the prevalence of fibrils in biological systems, their study is of great importance in the fields of microbiology, biomechanics, and materials science.
Rubidium is a chemical element; it has symbol Rb and atomic number 37. It is a very soft, whitish-grey solid in the alkali metal group, similar to potassium and caesium. Rubidium is the first alkali metal in the group to have a density higher than water. On Earth, natural rubidium comprises two isotopes: 72% is a stable isotope, 85Rb, and 28% is the slightly radioactive 87Rb, with a half-life of 48.8 billion years – more than three times as long as the estimated age of the universe. German chemists Robert Bunsen and Gustav Kirchhoff discovered rubidium in 1861 by the newly developed technique, flame spectroscopy. The name comes from the Latin word rubidus, meaning deep red, the color of its emission spectrum. Rubidium's compounds have various chemical and electronic applications. Rubidium metal is easily vaporized and has a convenient spectral absorption range, making it a frequent target for laser manipulation of atoms. Rubidium is not a known nutrient for any living organisms. However, rubidium ions have similar properties and the same charge as potassium ions, and are actively taken up and treated by animal cells in similar ways.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.